28 June 2012 - It was reported today that BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company, has announced positive results of a completed pharmacokinetic study examining the effects of multiple BEMA Buprenorphine/Naloxone (BNX) films administered concurrently.

The study is a part of the United States Food and Drug Administration recommended programme for a New Drug Application for BNX.

The study indicated that the buprenorphine pharmacokinetics was identical following multiple BNX films applied at one time compared to an equivalent dose administered as a single film.